Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Major Program(s) or Research Group(s)

  • Community Oncology and Prevention Trials
  • NCI Community Oncology Research Program
  • Supportive Care and Symptom Management

Sponsor

Alliance for Clinical Trials in Oncology

Status

Recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT04939090

This phase III trial compares the effects of olanzapine versus megestrol acetate in treating
loss of appetite in patients with cancer that has spread to other places in the body
(advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if
olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and
preventing weight loss.

Intervention

Megestrol Acetate, Olanzapine, Questionnaire Administration

Condition

Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm

Investigators

Aminah Jatoi, MD, Debra M. Prow, Bryan A. Faller, Kendrith M. Rowland, Deborah W. Wilbur, Joshua Lukenbill, Grant R. Seeger, Ki Y. Chung, Nicholas DiBella, Isoken Koko, Richard L. Deming, Tareq Al Baghdadi, Preston D. Steen, Jay W. Carlson

See list of participating sites